Money never sleeps pal. I just made $800,000 in Hong Kong gold. It's been wired to you -- play with it. You done good, but you gotta keep doing good.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GOOD MORNING EVERYBODY...........
HOat .73 but low volume.. I watched this one go down. It wont take much to move it back to $1
Amazing what a week will change in the market!!!!
Buffett is buying in a down market!!
Just not alot of Volume here right now ... It will retrace back up
Dow is a Cash Cow Right now for Day Traders.. In one day out the next and back in.. Never seen Such Movement in the down day after Day...
Movement Makes $$. This stock and the Dow are moving !!!!!!
Yes Green in a tuff market today!!
It will Bounce but right now people are running for the doors
ADVENTRX Receives Complete Response Letter for Exelbine NDA
print (NYSE Amex: ANX) announced today that it received a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the Company's New Drug Application (NDA) for Exelbine™ (vinorelbine injectable emulsion) for the treatment of non-small cell lung cancer.
The FDA determined that it could not approve the Exelbine NDA in its present form. In particular, the complete response letter noted that, based on inspections at clinical sites, the authenticity of the drug products used in the pivotal bioequivalence trial (Study 530-01) could not be verified, which placed the results of the trial into question. The letter stated that the bioequivalence trial will need to be repeated to address this deficiency.
In addition, the FDA requested information regarding product quality, or CMC matters. All CMC information requests in the complete response letter were the subject of FDA inquiries from earlier in the review cycle, and the Company had submitted responses to each request prior to receipt of the complete response letter.
"We are disappointed with the FDA's determination and, next week, plan to request a type A meeting to discuss its response. Following that meeting, we will be in a better position to comment on the future of our Exelbine program. However, we believe the authenticity of the drug products used in the pivotal study is verifiable and plan to discuss FDA's concerns in this regard. We also will inquire whether FDA has comments to our previously submitted responses," said Brian M. Culley, Chief Executive Officer of ADVENTRX
Are we trending back up...............
Good Morning Everybody!!!!!!!!
I dont see anything but down coming.. His bailouts are now just showing it allowed the rich to get richer since 08 and now the economy is stalling and debt is worse..
What can be done??
Be interesting around 2pm to see what the market does.....
Hey winks!! Great entry levels down here
Cyclacel Pharmaceuticals to Announce Release of Second Quarter 2011 Financial Results print
Cyclacel Pharmaceuticals, Inc. (MM) (NASDAQ:CYCC)
Intraday Stock Chart
Today : Tuesday 9 August 2011
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, will announce second quarter 2011 financial results on Thursday August 11, 2011. The Company will host a conference call and live webcast at 4:30 pm Eastern time on the same day.
Conference call information:
US/Canada call: (877) 493-9121/ international call: (973) 582-2750
US/Canada archive: (855) 859-2056/ international archive: (404) 537-3406
Code for live and archived conference call is 89030684
For the live and archived webcast, please visit the Corporate Presentations page on the Cyclacel website at www.cyclacel.com. The webcast will be archived for 90 days and the audio replay for 7 days.
About Cyclacel Pharmaceuticals, Inc.
Cyclacel is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Sapacitabine (CYC682), a cell cycle modulating nucleoside analog, is in Phase 3 development for the front-line treatment of acute myeloid leukemia in the elderly and Phase 2 studies for myelodysplastic syndromes and lung cancer. Seliciclib (CYC202 or R-roscovitine), a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 studies for the treatment of lung cancer and nasopharyngeal cancer and in a Phase 1 trial in combination with sapacitabine. Cyclacel's ALIGN Pharmaceuticals subsidiary markets directly in the U.S. Xclair® Cream for radiation dermatitis, Numoisyn® Liquid and Numoisyn® Lozenges for xerostomia. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates. Please visit www.cyclacel.com for additional information.
Forward-looking Statements
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety, and intended utilization of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its products, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and current filings that have been filed with the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact for Cyclacel Pharmaceuticals, Inc.
© Copyright 2011 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc. Numoisyn® and Xclair® are trademarks of Sinclair Pharma plc.
CONTACT: Investors/Media:
Corey Sohmer
(908) 517-7330
csohmer@cyclacel.com
IntelGenx Reports Q2, 2011 Results and Highlights Recent Developments Date : 08/09/2011 @ 6:00AM
Source : MarketWire
Stock : IntelGenx Technologies Corp. (IGXT)
Quote : 0.591 0.0 (0.00%) @ 8:04AM
IntelGenx Reports Q2, 2011 Results and Highlights Recent Developments
print
Intelgenx Technologs (OTCBB:IGXT)
Intraday Stock Chart
Today : Tuesday 9 August 2011
BEAR MARKET !!!!!!!!!!!!!
CYCC at .72 this Might be the Entry Point around this level... I'll be watching close to Get back into this stock
Nice to see something is selling.. Probably related to higher fuel costs
Bounce Play on alot of these stocks will be a easy 10%, But will have to see what Tues Brings first!
Did You get those .51's
Ouch!! .51's printed its hard to watch on the sideline know these are cheap shares. However we might see .40's before friday
Low volume here. At least nobody is dumping
The Media is sure putting some Negative information out... SUCKS!
Good Morning Everybody.... Might be a Bumpy Ride this Morning..
Add your shares at .55 .. ITS GOING!!!!!!!!!!!!!
Fridays suck after a big down day... I think will close Red
I think will see $10 share increase today. I grabbed yesteray afternoon in the mist of the Fear of the Media!!
Will see how the market plays out today.... Im happy if Oil keeps dropping and the rest rebounds!!
This will Bounce back but with all the quotes the media is throwing around the dow closing down over 500 points... Friday Might be a Bad day here...
I still see Great $$###$$ here in the up and coming months
Wall Street plunged on the worst one-day drop since December 2008. Stock investors face a number of worries. Congress and the administration must resume their debates over spending cuts to avoid a possible credit downgrade. Evidence of economic weakness has recently increased, raising fear of a return to a recession. A spreading debt crisis in Europe has also threatened to hit the global economy
Down down over 400.. Wait until people get home from work and watch the news.. Friday could be a free for all!!
I cant Wait!!
FOLKS THE STOCK MARKET IS GOING TO GET UGLY!! I DONT WANT TO BE IN IT ON FRIDAY!!
TIMBER!!!!!!!
Somebody Spent $425 on a Few shares ... LOL!!
Adding here winks!!!
I just added some shares here today winks... WIll see this week close on a green note....
I've Added more shares today......